Aesica Pharmaceuticals and CMIC HOLDINGS Sign Collaborative Agreement for International Business Expansion Across European, Japanese and US Markets

Aesica Pharmaceuticals Ltd, a global contract development and manufacturing organisation (CDMO), and CMIC HOLDINGS Co., Ltd, the leading Japanese-based CDMO with established sites in the US, have announced the signing of a Memorandum of Understanding for the reciprocal development of sales and marketing opportunities for respective clients in Europe and Japan. Furthermore, both companies will work closely together to develop commercial opportunities across the US market.      

Under the terms of the Memorandum of Understanding on collaborative agreement, Aesica and CMIC will exploit corporate synergies between the two companies and form a very close working relationship through which a collaborative approach to sales and marketing and customer liaison is set to be developed for the benefit of their customers. This initiative will form the initial basis of a supply and quality agreement.

Specifically, the reciprocal marketing of capabilities will be used by Aesica to proactively seek expansion of business opportunities in Japan and the US, collaborating with CMIC customers who may require consultation and manufacturing in Europe. Equally, CMIC is looking to expand global commercial business opportunities outside of the Japanese market, collaborating with Aesica customers who may require consultation or manufacturing in Japan. In addition, both parties will pursue joint collaborative development of the US market. 

Dr Robert Hardy, CEO of Aesica commented: “This agreement will provide a tremendous opportunity to develop business and commercial opportunities for our customers in the Japanese market and in the US, and provide solid scope for us to expand our market share in these regions. We look forward to forging an extremely close working relationship and partnership between our two companies”.

Kazuo Nakamura, Chairman and CEO of CMIC added: “There are tremendous synergies between CMIC and Aesica, which will be exploited to the full commercial benefit of customers of each company. CMIC is a leading Japanese, full service contract development and manufacturer of formulated products for the pharmaceutical industry, with established manufacturing sites in Japan, Korea and the US, and Aesica is an international CDMO operating in the UK, Germany and Italy across both API and formulated products. The combined, European, Japanese and US commercial expertise and presence is enormous.”